Breakthrough cancer medicine and its impact on novel drug development in China:report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting
the United States、clinical trial
TU5;R9
The authors would like to thank Dr. Pascal Qian and al Executive Members of USCACA for their contributions to the session and this report
2014-12-26(万方平台首次上网日期,不代表论文的发表时间)
共5页
620-624